You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 54 No. 5, May 1997 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLE
 This Article
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Recurrent supratentorial malignant gliomas in children. Long-term salvage therapy with oral etoposide

M. C. Chamberlain
Department of Neurosciences, University of California, San Diego, USA.

BACKGROUND: A long-term regimen of oral etoposide, a type of chemotherapy, is used in oncology and is effective in treating germ-cell tumors, lymphomas, Kaposi sarcoma, and primary brain tumors. OBJECTIVE: To examine the toxic effects and efficacy of long-term salvage chemotherapy using oral etoposide. PATIENTS AND METHODS: Fourteen children (8 boys and 6 girls) with recurrent supratentorial gliomas, ranging in age from 4 to 18 years (median age, 9 years), were treated with etoposide. Tumor histologic grades included Daumas-Duport grade 3 (10 children) and grade 4 astrocytomas (4 children). All children had been treated previously with radiotherapy (median dose, 60 Gy) and nitrosourea-based chemotherapy. Each cycle of therapy consisted of 21 days of etoposide (50 mg/m2 daily) followed by a 14-day period of rest and an additional 21 days of etoposide (50 mg/m2 daily). Measurements of complete blood cell counts were taken biweekly. A neurological examination and a magnetic resonance image of the brain with contrast medium were performed before each cycle of therapy. RESULTS: Treatment-related complications included the following partial alopecia (8 children); diarrhea (6 children); weight loss (4 children); anemia (4 children); neutropenia (4 children) and thrombocytopenia (4 children). Four children required transfusion (4 with packed red blood cells and 3 with platelets) and 2 children received antibiotic therapy for neutropenic fever. There were no treatment-related deaths. All children were examined for response. In 7 children (50%), the results of magnetic resonance imaging indicated either a partial response (3 children) or stable disease (4 children), with a median duration of response of 8 months. CONCLUSION: Oral etoposide is a well tolerated and relatively nontoxic chemotherapeutic agent with demonstrated activity in children with recurrent supratentorial gliomas.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Risk of Secondary Leukemia After a Solid Tumor in Childhood According to the Dose of Epipodophyllotoxins and Anthracyclines: A Case-Control Study by the Societe Francaise d'Oncologie Pediatrique
Le Deley et al.
JCO 2003;21:1074-1081.
ABSTRACT | FULL TEXT  

Antiangiogenic Scheduling of Chemotherapy Improves Efficacy against Experimental Drug-resistant Cancer
Browder et al.
Cancer Res. 2000;60:1878-1886.
ABSTRACT | FULL TEXT  

Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: The past decade and where we are heading
Levin
Neuro Oncol 1999;1:69-80.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.